Studies have shown that patients undergoing immunosuppression treatment, particularly with regard to tumor necrosis factor alpha (TNF-α), have an increased risk of TB; for example, the relative risk is 29.3 for patients taking adalimumab and 18.6 for those taking infliximab [3,4]. Here, TNF is linked to tuberculosis.